A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019

Abstract

AbstractBackgroundWe characterize the incidence and 5‐year survival of children and adolescents with neuroblastoma stratified by demographic and clinical factors based on the comprehensive data from United States Cancer Statistics (USCS) and the National Program of Cancer Registries (NPCR).MethodsWe analyzed the incidence of neuroblastoma from USCS (2003–2019) and survival data from NPCR (2001–2018) for patients less than 20 years old. Incidence trends were calculated by average annual percent change (AAPC) using joinpoint regression. Differences in relative survival were estimated comparing non‐overlapping confidence intervals (CI).ResultsWe identified 11,543 primary neuroblastoma cases in USCS. Age‐adjusted incidence was 8.3 per million persons [95% CI: 8.2, 8.5], with an AAPC of 0.4% [95% CI: −0.1, 0.9]. Five‐year relative survival from the NPCR dataset (n = 10,676) was 79.7% [95% CI: 78.9, 80.5]. Patients aged less than 1 year had the highest 5‐year relative survival (92.5%). Five‐year relative survival was higher for non‐Hispanic White patients (80.7%) or Hispanic patients (80.8%) compared to non‐Hispanic Black patients (72.6%).ConclusionNeuroblastoma incidence was stable during 2003–2019. Differences in relative survival exist by sex, age, race/ethnicity, and stage; patients who were male, older, non‐Hispanic Black, or with distant disease had worse survival. Future studies could seek to assess the upstream factors driving disparities in survival, and evaluate interventions to address inequities and improve survival across all groups.